Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma

Christopher Hoimes • 28 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin Pembrolizumab
EV-103

Christopher Hoimes, MD, PhD, of University Hospitals Seidman Cancer Center, Cleveland, OH, presents the initial results of the EV-103 trial of enfortumab vedotin plus pembrolizumab for locally advanced for metastatic urothelial carcinoma (NCT03288545). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals